151 related articles for article (PubMed ID: 38455400)
1. Efficacy and safety of disitamab vedotin after trastuzumab for HER2 positive breast cancer: a real-world data of retrospective study.
Li C; Sun L; Liu Z; Sun H; Wang X; Yu Q; Yu Z
Am J Cancer Res; 2024; 14(2):869-879. PubMed ID: 38455400
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.
Nie C; Xu W; Guo Y; Gao X; Lv H; Chen B; Wang J; Liu Y; Zhao J; Wang S; He Y; Chen X
BMC Cancer; 2023 Dec; 23(1):1239. PubMed ID: 38102538
[TBL] [Abstract][Full Text] [Related]
3. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial.
Wang Y; Gong J; Wang A; Wei J; Peng Z; Wang X; Zhou J; Qi C; Liu D; Li J; Lu M; Lu Z; Cao Y; Yuan J; Zhang R; Fang J; Zhang X; Shen L
EClinicalMedicine; 2024 Feb; 68():102415. PubMed ID: 38235421
[TBL] [Abstract][Full Text] [Related]
4. RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study.
Wang P; Xia L
BMC Cancer; 2023 Nov; 23(1):1083. PubMed ID: 37946161
[TBL] [Abstract][Full Text] [Related]
5. Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report.
Wu Q; He L; Luo J; Jin W; Xu Y; Wang C
Oncol Lett; 2022 Oct; 24(4):339. PubMed ID: 36039062
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.
Xu J; Zhang H; Zhang L; Chu X; Li Y; Li G; Nie C; Wang M; Guo Y
Cancer Med; 2023 Dec; 12(23):21159-21171. PubMed ID: 37935113
[TBL] [Abstract][Full Text] [Related]
7. Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance.
Chen M; Huang R; Chen R; Pan F; Shen X; Li H; Rong Q; An X; Xue C; Shi Y
Oncologist; 2024 Apr; ():. PubMed ID: 38574190
[TBL] [Abstract][Full Text] [Related]
8. Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report.
Qu F; Liu Q; Lu R; Li W
Front Oncol; 2023; 13():1245701. PubMed ID: 37711199
[TBL] [Abstract][Full Text] [Related]
9. HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.
Chen M; Yao K; Cao M; Liu H; Xue C; Qin T; Meng L; Zheng Z; Qin Z; Zhou F; Liu Z; Shi Y; An X
Cancer Immunol Immunother; 2023 Jul; 72(7):2309-2318. PubMed ID: 36897337
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation.
Hu Y; Chen F; Sun S; Xv L; Wang X; Wang M; Zhao S; Zhao Z; Li M
Front Oncol; 2024; 14():1312634. PubMed ID: 38344201
[TBL] [Abstract][Full Text] [Related]
11. Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review.
Li Y; Zhang J; Cai Z; Gao X; Zhang L; Lu Z; Wang X; Yu P; Li J; Fang F
Front Oncol; 2023; 13():1286392. PubMed ID: 38074635
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study.
Zhou YX; Wang JL; Mu XL; Zhu YJ; Chen Y; Liu JY
Aging (Albany NY); 2023 Dec; 15(24):15473-15488. PubMed ID: 38147019
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
Peng Z; Liu T; Wei J; Wang A; He Y; Yang L; Zhang X; Fan N; Luo S; Li Z; Gu K; Lu J; Xu J; Fan Q; Xu R; Zhang L; Li E; Sun Y; Yu G; Bai C; Liu Y; Zeng J; Ying J; Liang X; Xu N; Gao C; Shu Y; Ma D; Dai G; Li S; Deng T; Cui Y; Fang J; Ba Y; Shen L
Cancer Commun (Lond); 2021 Nov; 41(11):1173-1182. PubMed ID: 34665942
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report.
Fan S; He L; Sang D
Oncol Lett; 2023 Aug; 26(2):359. PubMed ID: 37545624
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917).
Nakayama T; Yoshinami T; Yasojima H; Kittaka N; Takahashi M; Ohtani S; Kim SJ; Kurakami H; Yamamoto N; Yamada T; Takata T; Masuda N
BMC Cancer; 2021 Jul; 21(1):795. PubMed ID: 34238257
[TBL] [Abstract][Full Text] [Related]
17. Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors.
Hu Y; Zhu Y; Wei X; Tang C; Zhang W
Drugs Today (Barc); 2022 Oct; 58(10):491-507. PubMed ID: 36305543
[TBL] [Abstract][Full Text] [Related]
18. RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).
Wen F; Lin T; Zhang P; Shen Y
Front Oncol; 2023; 13():1233196. PubMed ID: 38269021
[TBL] [Abstract][Full Text] [Related]
19. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
[TBL] [Abstract][Full Text] [Related]
20. Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study.
Wang A; Chen M; Li D; Shi J; Tang W; Zhang Z; Ren S
Clin Genitourin Cancer; 2024 Mar; 22(3):102085. PubMed ID: 38636170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
